In a major breakthrough, researchers have announced promising trial results for a new combination treatment of leukemia patients in the UK. The innovative therapy has been shown to significantly improve patient outcomes, offering fresh hope for those living with acute myeloid leukaemia (AML). According to NHS data, AML is one of the most common types of blood cancer, affecting over 2,500 people each year.
The study involved 123 patients with relapsed or refractory AML, who received a combination of two drugs: entinostat and lenalidomide. This treatment targets specific pathways in cancer cells, aiming to halt their growth and spread. NHS guidelines suggest that nearly half of patients with AML do not achieve complete remission with standard treatments.
However, the trial results show that 47% of participants achieved complete or partial remission, with some experiencing significant improvements in quality of life. While these findings are encouraging, further research is needed to confirm them and determine the optimal dosing regimen for future use. Dr Joseph Gardiner, Chief Medical Officer at Syndax, commented that 'these results demonstrate the potential for this combination therapy to improve outcomes for patients with AML'.